Nieland Thomas J F, Penman Marsha, Dori Limor, Krieger Monty, Kirchhausen Tomas
Department of Cell Biology, Harvard Medical School, and Center for Blood Research, Boston, MA 02115-5701, USA.
Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15422-7. doi: 10.1073/pnas.222421399. Epub 2002 Nov 18.
The high-density lipoprotein (HDL) receptor, scavenger receptor, class B, type I (SR-BI), mediates both the selective uptake of lipids, mainly cholesterol esters, from HDL to cells and the efflux of cholesterol from cells to lipoproteins. The mechanism underlying these lipid transfers is distinct from classic receptor-mediated endocytosis, but it remains poorly understood. To investigate SR-BI's mechanism of action and in vivo function, we developed a high-throughput screen to identify small molecule inhibitors of SR-BI-mediated lipid transfer in intact cells. We identified five compounds that in the low nanomolar to micromolar range block lipid transport (BLTs), both selective uptake and efflux. The effects of these compounds were highly specific to the SR-BI pathway, because they didn't interfere with receptor-mediated endocytosis or with other forms of intracellular vesicular traffic. Surprisingly, all five BLTs enhanced, rather than inhibited, HDL binding by increasing SR-BI's binding affinity for HDL (decreased dissociation rates). Thus, the BLTs provide strong evidence for a mechanistic coupling between HDL binding and lipid transport and may serve as a starting point for the development of pharmacologically useful modifiers of SR-BI activity and, thus, HDL metabolism.
高密度脂蛋白(HDL)受体,即B类I型清道夫受体(SR-BI),介导脂质(主要是胆固醇酯)从HDL到细胞的选择性摄取以及胆固醇从细胞到脂蛋白的流出。这些脂质转移的潜在机制不同于经典的受体介导的内吞作用,但其仍未得到充分理解。为了研究SR-BI的作用机制和体内功能,我们开发了一种高通量筛选方法,以鉴定完整细胞中SR-BI介导的脂质转移的小分子抑制剂。我们鉴定出了五种化合物,它们在低纳摩尔到微摩尔范围内阻断脂质转运(BLT),包括选择性摄取和流出。这些化合物的作用对SR-BI途径具有高度特异性,因为它们不干扰受体介导的内吞作用或其他形式的细胞内囊泡运输。令人惊讶的是,所有五种BLT通过增加SR-BI对HDL的结合亲和力(降低解离速率)来增强而非抑制HDL结合。因此,BLT为HDL结合与脂质转运之间的机制偶联提供了有力证据,并可能作为开发具有药理学用途的SR-BI活性调节剂以及HDL代谢调节剂的起点。